BioNTech, Regeneron Expand Collaboration on Combo for Lung Cancer

 

• BioNTech and Regeneron plan to jointly conduct clinical trials evaluating FixVac candidate BNT116 in combination with Libtayo for the treatment of advanced non-small cell lung cancer (NSCLC)

• The development costs for the trials will be equally shared between the parties

• The companies advance clinical development of FixVac and Libtayo combination to third tumor type building on their existing agreements in melanoma and prostate cancer by combining their complementary immunotherapies to pave the way for new treatment options in high medical need indications

https://finance.yahoo.com/news/biontech-regeneron-expand-strategic-collaboration-132700302.html